Outlook Therapeutics (OTLK) Non-Current Debt (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Non-Current Debt of $11.1 million for Q1 2026, down 47.14% year-over-year from $21.0 million in Q1 2025, and down 45.57% quarter-over-quarter from $20.4 million in Q2 2025.
Outlook Therapeutics (OTLK) Non-Current Debt (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Non-Current Debt for 10 consecutive years, with $11.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 47.14% year-over-year to $11.1 million; the TTM figure through Mar 2026 stood at $11.1 million (down 47.14% YoY), while the FY2021 annual figure was $10.9 million, up 1103.92% from the prior year.
- Non-Current Debt retreated to $11.1 million in Q1 2026 per OTLK's latest filing, from $20.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $31.8 million in Q4 2022 and bottomed at $11.1 million in Q1 2026.
- Historically, Non-Current Debt has averaged $21.1 million across 3 years, with a median of $20.7 million in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Debt jumped 231.31% — and 2026, when it tumbled 47.14%.
- Outlook Therapeutics' Non-Current Debt stood at $31.8 million in 2022, then tumbled by 35.77% to $20.4 million in 2025, then plunged by 45.57% to $11.1 million in 2026.
- Business Quant data shows OTLK's Non-Current Debt at $11.1 million in Q1 2026, $20.4 million in Q2 2025, and $21.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.12 Mn |
| Jun 30, 2025 | 20.44 Mn |
| Mar 31, 2025 | 21.05 Mn |
| Dec 31, 2022 | 31.82 Mn |
| Dec 31, 2021 | 9.60 Mn |
| Sep 30, 2021 | 10.89 Mn |
| Mar 31, 2021 | 129,171.00 |
| Dec 31, 2020 | 10.66 Mn |
| Sep 30, 2020 | 904,200.00 |
| Jun 30, 2020 | 544,924.00 |
| Mar 31, 2020 | 25,709.00 |
| Dec 31, 2019 | 38,011.00 |
| Sep 30, 2019 | 50,285.00 |
| Jun 30, 2019 | 3.60 Mn |
| Mar 31, 2019 | 75,073.00 |
| Dec 31, 2018 | 86,947.00 |
| Sep 30, 2018 | 98,487.00 |
| Jun 30, 2018 | 111,541.00 |
| Mar 31, 2018 | 4.60 Mn |
| Dec 31, 2017 | 143,488.00 |